Products for Research Use Only
RegisterLogin

AS2863619

CAT: 0804-HY-126675A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-126675A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene[1].
CAS Number
2241300-51-4
UNSPSC
12352005
Target
CDK; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/as2863619.html
Purity
98.02
Solubility
DMSO : 250 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
NC1=NON=C1C(N2C3=CC=C4N=C(C)NC4=C3)=NC5=C2C=CN=C5.[H]Cl.[H]Cl
Molecular Formula
C16H14Cl2N8O
Molecular Weight
405.24
References & Citations
[1]Akamatsu M, et al. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Sci Immunol. 2019 Oct 25;4 (40) . pii: eaaw2707.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK19; CDK8; GSK-3α; GSK-3β; STAT5
Citation 01
Biomaterials. 2026 Feb:325:123574.|bioRxiv. 2025 Nov 20.|Cell Stem Cell. 2024 Jun 6;31 (6) :795-802.e6.|Elife. 2023 Dec 6:12:RP88874.|Patent. US20250230411A1.|JCI Insight. 2025 Jul 8;10 (15) :e182050.

Alternative Products

CatalogName
BA3757-1AS2863619
A22338-5AS2863619 5mg
A22338-1AS2863619 1mg
A22338-100AS2863619 100mg
A22338-25AS2863619 25mg
A22338-10AS2863619 10mg

Popular Products